NCT03089775View on ClinicalTrials.gov

Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

May 24, 2017

Study Completion Date

May 24, 2017

Conditions
Contact Dermatitis
Interventions
DRUG

BBI-2000

Experimental

DRUG

Vehicle

Vehicle Comparator

OTHER

Multiple treatments

BBI-2000, Vehicle, Clobetasol Propionate, No treatment

Trial Locations (1)

H2K 4L5

Innovaderm Research Inc., Montreal

Sponsors
All Listed Sponsors
lead

Fresh Tracks Therapeutics, Inc.

INDUSTRY

NCT03089775 - Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis | Biotech Hunter | Biotech Hunter